Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission  Julie M Vose, Douglas J Rizzo, Jing Tao-Wu, James O Armitage, Asad Bashey, Linda J Burns, Neal Paul Christiansen, Cesar O Freytes, Robert Peter Gale, John Gibson, Sergio A Giralt, Roger H Herzig, Charles F Lemaistre, Philip L McCarthy, Stephen D Nimer, Finn B Petersen, David P Schenkein, Peter H Wiernik, Joseph M Wiley, Fausto R Loberiza, Hillard M Lazarus, Koen van Biesen, Mary M Horowitz  Biology of Blood and Marrow Transplantation  Volume 10, Issue 2, Pages 116-127 (February 2004) DOI: 10.1016/j.bbmt.2003.09.015

Figure 1 Probability of overall and progression-free survival in patients who underwent transplantation in CR 2 or Rel 1 for diffuse aggressive NHL. Biology of Blood and Marrow Transplantation 2004 10, 116-127DOI: (10.1016/j.bbmt.2003.09.015)

Figure 2 Probability of progression-free survival by time from diagnosis to relapse before transplantation. Biology of Blood and Marrow Transplantation 2004 10, 116-127DOI: (10.1016/j.bbmt.2003.09.015)

Figure 3 Probability of progression-free survival by age at the time of transplantation. Biology of Blood and Marrow Transplantation 2004 10, 116-127DOI: (10.1016/j.bbmt.2003.09.015)

Figure 4 Probability of progression-free survival in patients who received or did not receive myeloid growth factors after transplantation for enhanced myeloid recovery and graft type. Biology of Blood and Marrow Transplantation 2004 10, 116-127DOI: (10.1016/j.bbmt.2003.09.015)

Figure 5 Probability of relapse in patients who received or did not receive myeloid growth factor after transplantation for enhanced myeloid recovery and graft type. Biology of Blood and Marrow Transplantation 2004 10, 116-127DOI: (10.1016/j.bbmt.2003.09.015)